D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Hosted on MSN4d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Contract Pharma5d
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab
Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.
Nasdaq5d
Vanda Inks Exclusive License Agreement With AnaptysBio For Imsidolimab Development
(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), on Monday, announced it has entered into an exclusive global license agreement with AnaptysBio Inc. (ANAB) for the development and commercialization ...
Yahoo Finance5d
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of ...
Vanda, Anaptys Join on Development Pact
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...